EP Patent

EP4249055A2 — Tofacitinib oral sustained release dosage forms

Assigned to Pfizer Inc · Expires 2023-09-27 · 3y expired

What this patent protects

The present invention relates to an oral sustained release dosage form of tofacitinib, specifically to a core for use in an extrudable core system tablet comprising tofacitinib citrate. Such a tablet has desirable pharmacokinetic characteristics.

USPTO Abstract

The present invention relates to an oral sustained release dosage form of tofacitinib, specifically to a core for use in an extrudable core system tablet comprising tofacitinib citrate. Such a tablet has desirable pharmacokinetic characteristics.

Drugs covered by this patent

Patent Metadata

Patent number
EP4249055A2
Jurisdiction
EP
Classification
—
Expires
2023-09-27
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.